Twist Bioscience (NASDAQ:TWST) Releases Earnings Results

Twist Bioscience (NASDAQ:TWST) released its quarterly earnings results on Friday. The company reported ($0.81) EPS for the quarter, topping the consensus estimate of ($0.92) by $0.11, MarketWatch Earnings reports. Twist Bioscience had a negative return on equity of 29.09% and a negative net margin of 88.97%. The business had revenue of $66.95 million for the quarter, compared to analysts’ expectations of $63.35 million. During the same quarter in the previous year, the firm posted ($0.91) earnings per share. The company’s revenue was up 16.8% compared to the same quarter last year.

Twist Bioscience Trading Up 25.9 %

NASDAQ:TWST opened at $24.01 on Friday. The firm has a market capitalization of $1.38 billion, a PE ratio of -6.49 and a beta of 1.32. The stock has a 50 day moving average of $18.69 and a 200-day moving average of $19.07. Twist Bioscience has a 52 week low of $11.46 and a 52 week high of $31.51.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Captrust Financial Advisors lifted its stake in Twist Bioscience by 101.3% during the second quarter. Captrust Financial Advisors now owns 759 shares of the company’s stock valued at $27,000 after purchasing an additional 382 shares during the last quarter. Canada Pension Plan Investment Board lifted its stake in Twist Bioscience by 155.6% during the first quarter. Canada Pension Plan Investment Board now owns 1,066 shares of the company’s stock valued at $52,000 after purchasing an additional 649 shares during the last quarter. Lazard Asset Management LLC lifted its position in shares of Twist Bioscience by 73.4% in the 1st quarter. Lazard Asset Management LLC now owns 1,597 shares of the company’s stock valued at $78,000 after acquiring an additional 676 shares in the last quarter. US Bancorp DE lifted its position in shares of Twist Bioscience by 257.1% in the 2nd quarter. US Bancorp DE now owns 2,050 shares of the company’s stock valued at $42,000 after acquiring an additional 1,476 shares in the last quarter. Finally, Amundi lifted its position in shares of Twist Bioscience by 30.5% in the 4th quarter. Amundi now owns 3,550 shares of the company’s stock valued at $95,000 after acquiring an additional 830 shares in the last quarter.

Analysts Set New Price Targets

Several research firms recently commented on TWST. Robert W. Baird boosted their price target on Twist Bioscience from $18.00 to $27.00 in a research note on Monday, August 7th. Barclays boosted their price target on Twist Bioscience from $20.00 to $26.00 and gave the stock an “overweight” rating in a research note on Monday, August 7th. Finally, Berenberg Bank initiated coverage on Twist Bioscience in a research note on Wednesday, September 27th. They issued a “buy” rating and a $27.00 price target on the stock. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $28.43.

About Twist Bioscience

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium.